The Efficacy of Exercise Interventions in Reducing Side Effects in Young Women with Breast Cancer: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 30 (3) ◽  
pp. 189-205
Author(s):  
Caroline Anna Head ◽  
Alexandra Danks ◽  
Tiffany McKinley ◽  
Kellie Moher ◽  
Jenna Smith-Turchyn
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Side Effects ◽  
Young Women ◽  
Meta Analysis ◽  
Exercise Interventions

scholarly journals Quantifying the Lasting Effects of Resistance and Endurance Exercise Interventions on Mental Wellbeing and Physical Fitness in Women Receiving Adjuvant Treatment for Breast Cancer Compared to Adjuvant Therapy Alone: A Contemporary Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Jonathon Mok ◽  
Marie-Juliet Brown ◽  
Elizabeth Akam ◽  
Mhairi Morris
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Side Effects ◽  
Adjuvant Therapy ◽  
Physical Fitness ◽  
Adjuvant Treatment ◽  
Meta Analysis ◽  
Mental Wellbeing ◽  
Clinical Value ◽  
Exercise Interventions

Abstract Introduction: Breast cancer is a persisting global burden for health services with cases and deaths projected to rise in future years. Surgery complemented by adjuvant therapy is commonly used to treat breast cancer, however comes with detrimental side effects to physical fitness and mental wellbeing. Aim: The aim of this systematic review and meta-analysis is to determine whether resistance and endurance interventions performed during adjuvant treatment can lastingly ameliorate these side effects.Methods: A systematic literature search was performed in various electronic databases. Papers were assessed for bias and grouped based on intervention design. RStudio was used to perform the meta-analyses for each group using the ‘meta’ package. Publication bias and power analyses were also conducted. These methods conform to PRISMA guidelines.Results: Combined resistance and endurance interventions elicited significant long-lasting improvements in global fatigue and were beneficial to the remaining side effects. Individually, resistance and endurance interventions non-significantly improved these side effects. Resistance interventions elicited higher benefits overall.Conclusion: Exercise interventions have lasting clinical benefits in ameliorating adjuvant therapy side effects, which negatively impact physical fitness and mental wellbeing. These interventions are of clinical value to enhance adherence rates and avoid comorbidities such as sarcopenia, thus improving disease prognosis.

scholarly journals Chinese Herbal Medicine for Reducing Chemotherapy-Associated Side-Effects in Breast Cancer Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 10 ◽  
Author(s):  
Sha Li ◽  
Tsz-him So ◽  
Guoyi Tang ◽  
Hor-Yue Tan ◽  
Ning Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Side Effects ◽  
Herbal Medicine ◽  
Cancer Patients ◽  
Chinese Herbal Medicine ◽  
Meta Analysis ◽  
Chemotherapeutic Agents ◽  
Breast Cancer Patients ◽  
Chinese Herbal

BackgroundChemotherapy usually induces a variety of side-effects in cancer treatment as it cannot tell normal cells apart from cancer cells and kills both. Chinese herbal medicine (CHM) has been regarded as a potential effective intervention for relieving the side-effects of chemotherapy in breast cancer patients.ObjectiveThis study aims to conduct a comprehensive systematic review and meta-analysis to evaluate the efficacy of CHM as adjuvant therapy for reducing the chemotherapy-induced side-effects in the treatment of breast cancer.MethodsMain electronic databases were searched up to May 2020 for Randomized Controlled Trials (RCTs) evaluating the effect of CHM on breast cancer patients with chemotherapy. The PRISMA statement was adopted in this study and meta-analyses were performed.ResultsThe included studies showed unsatisfied quality. Results based on available literature indicated that the adjunctive use of CHM with chemotherapy may reduce the chemotherapeutic agents-associated adverse events, including nausea and vomiting, diarrhea, alopecia, myelosuppression, and impaired immune function.ConclusionA confident conclusion could not be have due to the lack of large scale and high quality trials.

scholarly journals Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 (8) ◽  
pp. 704
Author(s):  
Alessia Romito ◽  
Sonia Bove ◽  
Ilaria Romito ◽  
Drieda Zace ◽  
Ivano Raimondo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Publication Bias ◽  
Young Women ◽  
Ovarian Reserve ◽  
Case Reports ◽  
Meta Analysis ◽  
Case Series ◽  
Female Population ◽  
Before And After

Background: Worldwide, breast cancer (BC) is the most common malignancy in the female population. In recent years, its diagnosis in young women has increased, together with a growing desire to become pregnant later in life. Although there is evidence about the detrimental effect of chemotherapy (CT) on the menses cycle, a practical tool to measure ovarian reserve is still missing. Recently, anti-Mullerian hormone (AMH) has been considered a good surrogate for ovarian reserve. The main objective of this paper is to evaluate the effect of CT on AMH value. Methods: A systematic review and meta-analysis were conducted on the PubMed and Scopus electronic databases on articles retrieved from inception until February 2021. Trials evaluating ovarian reserves before and after CT in BC were included. We excluded case reports, case-series with fewer than ten patients, reviews (narrative or systematic), communications and perspectives. Studies in languages other than English or with polycystic ovarian syndrome (PCOS) patients were also excluded. AMH reduction was the main endpoint. Egger’s and Begg’s tests were used to assess the risk of publication bias. Results: Eighteen trials were included from the 833 examined. A statistically significant decline in serum AMH concentration was found after CT, persisting even after years, with an overall reduction of −1.97 (95% CI: −3.12, −0.82). No significant differences in ovarian reserve loss were found in the BRCA1/2 mutation carriers compared to wild-type patients. Conclusions: Although this study has some limitations, including publication bias, failure to stratify the results by some important factors and low to medium quality of the studies included, this metanalysis demonstrates that the level of AMH markedly falls after CT in BC patients, corresponding to a reduction in ovarian reserve. These findings should be routinely discussed during oncofertility counseling and used to guide fertility preservation choices in young women before starting treatment.

scholarly journals Six-Minute Walk Distance in Breast Cancer Survivors—A Systematic Review with Meta-Analysis

2021 ◽  
Vol 18 (5) ◽  
pp. 2591
Author(s):  
Jasna But-Hadzic ◽  
Mirza Dervisevic ◽  
Damir Karpljuk ◽  
Mateja Videmsek ◽  
Edvin Dervisevic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Survivors ◽  
Cardiorespiratory Fitness ◽  
Healthy Subjects ◽  
Breast Cancer Survivors ◽  
Meta Analysis ◽  
Normative Values ◽  
Exercise Interventions ◽  
Minute Walk

The six-minute walk test (6MWT) is a widely used test for the indirect measurement of cardiorespiratory fitness in various cancer populations. Although the 6MWT is a simple test, there are no normative values for breast cancer survivors (BCS) or comparisons of results with healthy counterparts. A systematic review with a meta-analysis was carried out, which included studies from 2007 to 2020. Ninety-one studies were found, 21 of which were included in the quantitative synthesis. Among them were 9 randomized controlled trials (RCT), 8 prospective cohort studies and 4 cross-sectional studies. A total of 1084 BCS were included. Our results revealed that healthy subjects (n = 878) covered a significantly greater distance than BCS during the 6MWT (589.9 m vs. 477.4 m, p < 0.001), and the results of the meta-regression analysis showed that the 6MWD was predicted by the participants’ BMI (p < 0.001), but not by their age (p = 0.070). After adjustment for BMI, the healthy subjects also covered greater distances than the BCS (103 m; p < 0.001). The normative values of 6MWT were presented for BCS. Besides, 6MWT distances distinguish between their healthy counterparts, therefore, the 6MWT distance is a relevant parameter for the assessment and monitoring of cardiorespiratory fitness in medical and exercise interventions for BCS.

A systematic review and meta-analysis of randomized controlled trials to evaluate the risk of gastrointestinal and hepatic toxicities in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors.

2017 ◽  
Vol 35 (31_suppl) ◽  
pp. 209-209
Author(s):  
Myo Zaw ◽  
Kyaw Zin Thein ◽  
Aung Tun ◽  
Myat M. Han ◽  
Yu Yu Thar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Side Effects ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Endocrine Resistance ◽  
Controlled Trials ◽  
High Grade ◽  
Randomized Controlled ◽  
Gi Symptoms

209 Background: Hormonal therapies function through CDK4/CDK6/E2F axis which is essential in luminal estrogen receptor positive breast cancer. Reactivation of these CDK4 and CDK6 kinases has been implicated in endocrine resistance. Many CDK 4/6 inhibitors were employed in studies with noteworthy safety concerns. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the risk of gastrointestinal (GI) and hepatic toxicities. Methods: MEDLINE, EMBASE databases and meeting abstracts from inception through June 2017 were queried. RCTs that mention GI symptoms and elevation of liver enzymes as adverse effects were incorporated in the analysis. Mantel-Haenszel method was used to calculate the estimated pooled risk ratio with 95% confidence interval (CI). Results: We included five RCTs with a total of 2671 patients treated with CDK 4/6 inhibitors. The study arm used palbociclib-letrozole, palbociclib-fulvestrant, ribociclib-letrozole and abemaciclib-fulvestrant while the control arm used placebo in combination with letrozole or fulvestrant. The relative risks (RR) of all-grade side effects were as follows: diarrhea, 1.72 (95% CI: 1.08 – 2.74, p = 0.02); stomatitis, 2.62 (95% CI: 1.43 – 4.79, p = 0.002); nausea, 1.59 (95% CI: 1.30–1.94; p < 0.0001); vomiting, 1.65 (95% CI: 1.06–2.56; p = 0.02); elevated AST, 2.30 (95% CI: 1.34–3.93; p = 0.002); and elevated ALT, 2.78 (95% CI: 1.90–4.08; p < 0.0001). The RR of high-grade side effects were as follows: diarrhea, 2.26 (95% CI: 0.39 – 13.09, p = 0.36); stomatitis, 2.14 (95% CI: 0.36 – 12.72, p = 0.40); nausea, 1.13 (95% CI: 0.28 –4.47; p = 0.86); vomiting, 0.79 (95% CI: 0.24 – 2.54; p = 0.69); elevated AST, 1.85 (95% CI: 0.74 – 4.64; p = 0.18); and elevated ALT, 4.33 (95% CI: 2.15 – 8.71; p < 0.0001). Conclusions: The risk of developing any-grade diarrhea, stomatitis, nausea, vomiting and elevated AST and ALT, was high in CDK 4/6 inhibitors based regimen. Moreover, it increased the risk of high-grade elevated ALT.

Sign in / Sign up

Export Citation Format

Share Document